Somatostatin receptor expression in clinical immunology

P. M. Van Hagen*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

42 Citations (Scopus)

Abstract

Specific somatostatin receptors (ssts) have been described in normal and tumor tissues and identified on more than 95% of normal mitogen-activated human peripheral lymphocytes. Somatostatin may modulate the immune response by a variety of mechanisms, most of which are inhibitory, sst scintigraphy in patients with immune-mediated diseases revealed sst expression in 97% of patients with sarcoidosis, 100% of patients with tuberculosis or Wegener's granulomatosis, 75% of patients with Sjögren's syndrome, and 50% of patients with systemic lupus erythematosus or uveitis. sst expression appeared to be related to progression or remission of disease. Patients who responded poorly to therapy remained positive at scintigraphy. Investigation of 10 human B-cell lines and eight human T-cell lines, using a polymerase chain reaction, revealed the presence of sst2-mRNA in two of the B-cell and two of the T-cell lines. Visualization of ssts on activated mononuclear leukocytes by sst scintigraphy may prove useful in evaluating the spread of immune-mediated diseases and their responses to therapy. The efficacy of octreotide should be studied in patients with these diseases.

Original languageEnglish
Pages (from-to)86-87
Number of pages2
JournalMetabolism: Clinical and Experimental
Volume45
Issue numberSUPPL.1
DOIs
Publication statusPublished - Aug 1996

Bibliographical note

© 1996 Published by Elsevier Inc.

Fingerprint

Dive into the research topics of 'Somatostatin receptor expression in clinical immunology'. Together they form a unique fingerprint.

Cite this